Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Arrowhead Pharmaceuticals (ARWR) over the last 13 years, with Q4 2025 value amounting to $10.7 million.

  • Arrowhead Pharmaceuticals' Other Accumulated Expenses rose 232613.64% to $10.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $10.7 million, marking a year-over-year increase of 232613.64%. This contributed to the annual value of $10.8 million for FY2025, which is 240254.63% up from last year.
  • Latest data reveals that Arrowhead Pharmaceuticals reported Other Accumulated Expenses of $10.7 million as of Q4 2025, which was up 232613.64% from $10.8 million recorded in Q3 2025.
  • Arrowhead Pharmaceuticals' Other Accumulated Expenses' 5-year high stood at $10.8 million during Q3 2025, with a 5-year trough of $17000.0 in Q1 2021.
  • Over the past 4 years, Arrowhead Pharmaceuticals' median Other Accumulated Expenses value was $448000.0 (recorded in 2025), while the average stood at $2.9 million.
  • Within the past 5 years, the most significant YoY rise in Arrowhead Pharmaceuticals' Other Accumulated Expenses was 240254.63% (2025), while the steepest drop was 2181.5% (2025).
  • Quarter analysis of 4 years shows Arrowhead Pharmaceuticals' Other Accumulated Expenses stood at $17000.0 in 2021, then surged by 2611.76% to $461000.0 in 2023, then fell by 4.56% to $440000.0 in 2024, then soared by 2326.14% to $10.7 million in 2025.
  • Its last three reported values are $10.7 million in Q4 2025, $10.8 million for Q3 2025, and $7.4 million during Q2 2025.